Protagonist Therapeutics, Inc.
PTGX
$96.75
$4.394.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -147.29% | -73.13% | -69.38% | -65.34% | 448.54% |
| Total Depreciation and Amortization | -55.79% | -15.92% | -15.07% | -12.64% | -12.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.63% | 29.44% | 31.29% | 24.22% | 15.09% |
| Change in Net Operating Assets | 219.25% | -165.78% | -253.90% | 196.29% | -528.41% |
| Cash from Operations | -68.68% | -71.57% | -82.92% | 632.15% | 362.19% |
| Capital Expenditure | -17.34% | -65.04% | -252.53% | -97.15% | -122.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 83.99% | 70.05% | -62.98% | -844.46% | -671.37% |
| Cash from Investing | 83.53% | 69.64% | -63.82% | -829.85% | -662.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -11.76% | 6.92% | -33.07% | -79.95% | -84.55% |
| Repurchase of Common Stock | 20.17% | 20.17% | 20.17% | 62.25% | 21.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -11.56% | 7.65% | -33.24% | -80.10% | -84.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.87% | 82.55% | -255.52% | -173.34% | -246.73% |